RabMAb primary antibodies are generated using a unique and proprietary method of monoclonal antibody development from rabbits rather than the conventional method of starting with mice or rats.
The basic principle for making a RabMAb primary antibody is the same as for mouse monoclonals. Proprietary rabbit fusion partner cells can fuse to rabbit B-cells to create the Rabbit Hybridoma cells, true rabbit-to-rabbit hybridomas (1).
Hybridomas are then screened to select for clones with specific and sensitive antigen recognition and the antibodies are characterized using a variety of methods (view the process of RabMAb creation below).
Unlike traditional murine antibodies, antibodies generated with RabMAb technology provide better antigen recognition (2). The reason for this is that the rabbit immune system generates antibody diversity and optimizes affinity by mechanisms that are more efficient than those of mice and other rodents. This increases the possibility of obtaining a functional antibody that will work in a variety of applications (3, 4).
Additionally, many small compounds and peptides do not elicit a good immune response in mice but do favorably in rabbits. It is often for this reason that rabbit polyclonal antibodies are developed and used in many research and diagnostic applications, ranging from drug screening to clinical diagnosis.
In conclusion, RabMAb primary antibodies bring the combined benefits of superior antigen recognition of a rabbit immune system with the specificity and consistency of a monoclonal antibody, providing antibodies with superior binding affinity and bioactivity in a wide variety of biological assays.